Specify a stock or a cryptocurrency in the search bar to get a summary
Enlivex Therapeutics Ltd
ENLVEnlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel. Address: 14 Einstein Street, Ness Ziona, Israel, 7403618
Analytics
WallStreet Target Price
12 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ENLV
Dividend Analytics ENLV
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ENLV
Stock Valuation ENLV
Financials ENLV
Results | 2019 | Dynamics |